Therefore, our results imply that treatments for AD may also need to be disease stage-oriented: Aβ and tau may be appropriate targets early in the disease course, but the restoration of brain glucose metabolism should be explored as a treatment strategy for clinical AD. This evidence concerns the gene MAPT and Alzheimer disease.